- Home
- INSM
INSM
Insmed Incorporated
as 11-20-2024 4:00pm EST
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 12.5B | IPO Year: | 2000 |
| Target Price: | $83.64 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.92 - $80.53 | Next Earning Date: | 10-31-2024 |
| Revenue: | $342,958,000 | Revenue Growth: | 22.13% |
| Revenue Growth (this year): | 18.96% | Revenue Growth (next year): | 41.96% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Michael Alexander | INSM | Chief Legal Officer | Sep 13 '24 | Sell | $74.46 | 27,871 | $2,072,223.36 | 76,856 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Sep 12 '24 | Sell | $74.91 | 41,040 | $3,074,177.42 | 106,134 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Sep 10 '24 | Sell | $71.63 | 37,575 | $2,686,614.57 | 100,100 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Sep 6 '24 | Sell | $71.65 | 149,002 | $10,613,387.23 | 106,134 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Sector Update: Health Care Stocks Decline
MT Newswires
2 days ago
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
MT Newswires
2 days ago
Insmed Terminates $500 Million Share Sale Agreement With Leerink
PR Newswire
14 days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire
15 days ago
Insmed To Present at November 2024 Investor Conferences
Zacks
17 days ago
Insmed (INSM) Reliance on International Sales: What Investors Need to Know
Insider Monkey
20 days ago
Do You Believe in the Growth Potential of Insmed (INSM)?
Zacks
20 days ago
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.